Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL6568790

CCCCCCCCCCCCC(C)C(C)(C)Br.N

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.41
SPHK1 Q9NYA1 1/20 0.39
LMNA P02545 1/20 0.38
LCK P06239 1/20 0.38
PPARD Q03181 1/20 0.38
ZDHHC20 Q5W0Z9 1/20 0.38
ZDHHC2 Q9UIJ5 1/20 0.38
DNM1 Q05193 2/20 0.37
TSHR P16473 2/20 0.36
ADH1B P00325 1/20 0.36
ADH1C P00326 1/20 0.36
ADH1A P07327 1/20 0.36
ADH4 P08319 1/20 0.36
ADH7 P40394 1/20 0.36
THRB P10828 1/20 0.36
CA2 P00918 1/20 0.36
ACE2 Q9BYF1 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GPR84 Q9NQS5 2/20 0.34
FDPS P14324 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL8363598 1.00 OPRM1 (0.41) OPRM1SPHK1LMNALCKPPARD
Ammonia Solution, Strong SCHEMBL1344181 1.00 OPRM1 (0.41) OPRM1SPHK1LMNALCKPPARD
Ammonia Solution, Strong SCHEMBL2110651 1.00 OPRM1 (0.41) OPRM1SPHK1LMNALCKPPARD
Ammonia Solution, Strong SCHEMBL9803720 1.00 OPRM1 (0.41) OPRM1SPHK1LMNALCKPPARD
Ammonia Solution, Strong SCHEMBL3952379 1.00 OPRM1 (0.41) OPRM1SPHK1LMNALCKPPARD
SCHEMBL27867791 0.98 OPRM1 (0.42) OPRM1SPHK1LMNALCKPPARD
Phosphine SCHEMBL28272934 0.95 OPRM1 (0.41) OPRM1SPHK1LMNALCKPPARD
Trimethylammonium SCHEMBL28424587 0.91 OPRM1 (0.38) OPRM1SPHK1LMNALCKPPARD
Ammonia Solution, Strong SCHEMBL7236156 0.83 OPRM1 (0.38) OPRM1SPHK1LMNALCKPPARD
Ammonia Solution, Strong SCHEMBL27986318 0.82 OPRM1 (0.46) OPRM1SPHK1LMNADNM1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024008014-A1 PHARMACEUTICAL COMPOSITION FOR RESISTING INFECTION WITH SARS-COV-2 OR MUTANT THEREOF, AND COMBINED DRUG THEREOF 成都威斯克生物医药有限公司 2024-01-11 WO claimed
CN-115531617-B Gastrostomy catheter coated with lipopolysaccharide compound 上海市徐汇区大华医院 2023-09-29 CN claimed
CN-115414536-A Gene elution balloon and preparation method and application thereof 苏州中天医疗器械科技有限公司 2022-12-02 CN claimed
US-20190350200-A1 SYNERGISTIC ANTIMICROBIAL COMPOSITIONS JUBILANT LIFE SCIENCES LIMITED (IN) 2019-11-21 US claimed
EP-3534708-A1 SYNERGISTIC ANTIMICROBIAL COMPOSITIONS Jubilant Life Sciences Limited (IN) 2019-09-11 EP claimed
US-20150313846-A1 PROLONGED-RELEASE MULTIMICROPARTICULATE ORAL PHARMACEUTICAL FORM FLAMEL IRELAND LIMITED (IE) 2015-11-05 US claimed
CN-119970640-A Novel nucleic acid delivery system based on phosphatidylmitoxantrone and preparation method and application thereof 华东理工大学 2025-05-13 CN disclosed
CN-116004728-B Polymer-coated lipid nanoparticle, preparation method thereof and pharmaceutical preparation 深圳大学总医院 2025-02-28 CN disclosed
WO-2024193380-A1 VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTION 成都威斯克生物医药有限公司 2024-09-26 WO disclosed
WO-2024138921-A1 NON-HEPATIC TARGETING NUCLEIC ACID NANO-FORMULATION, PREPARATION METHOD THEREFOR, AND USE THEREOF 华南理工大学 2024-07-04 WO disclosed
CN-114099699-B Nanometer delivery system and preparation method and application thereof 华南理工大学 2024-03-19 CN disclosed
WO-2024008014-A1 PHARMACEUTICAL COMPOSITION FOR RESISTING INFECTION WITH SARS-COV-2 OR MUTANT THEREOF, AND COMBINED DRUG THEREOF 成都威斯克生物医药有限公司 2024-01-11 WO disclosed
CN-115531617-B Gastrostomy catheter coated with lipopolysaccharide compound 上海市徐汇区大华医院 2023-09-29 CN disclosed
US-8697098-B2 Polymer conjugated protein micelles SOUTH DAKOTA STATE UNIVERSITY (US) 2014-04-15 US disclosed
EP-2678001-A2 POLYMER CONJUGATED PROTEIN MICELLES South Dakota State University (US) 2014-01-01 EP disclosed
WO-2013188740-A1 ANTI-PSMA ANTIBODIES CONJUGATED TO NUCLEAR RECEPTOR LIGAND POLYPEPTIDES AMBRX, INC. (US) 2013-12-19 WO disclosed
US-20120219600-A1 POLYMER CONJUGATED PROTEIN MICELLES SOUTH DAKOTA STATE UNIVERSITY 2012-08-30 US disclosed
WO-2012116272-A2 POLYMER CONJUGATED PROTEIN MICELLES SOUTH DAKOTA STATE UNIVERSITY (US) 2012-08-30 WO disclosed
EP-1480679-A1 PHARMACEUTICAL FORMULATION OF IRESSA COMPRISING A WATER-SOLUBLE CELLULOSE DERIVATIVE Astrazeneca AB (SE) 2004-12-01 EP disclosed
WO-2003072139-A1 PHARMACEUTICAL FORMULATION OF IRESSA COMPRISING A WATER-SOLUBLE CELLULOSE DERIVATIVE ASTRAZENECA AB (SE) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120219600-A1 POLYMER CONJUGATED PROTEIN MICELLES MTDH, PSMG3, GHITM OPRM1 2781/4885SPHK1 3769/4885LMNA 1032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.